Get started
Author

Jianxuan Zou

Observed name: Jianxuan M. Zou
ORCID: 0000-0001-7241-9191
Observed ORCID: 0000-0001-7241-9191
OpenAlex ID: A5050315280
Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
2020 · Fazal Shirazi, Richard J. Jones, et al. · Proceedings of the National Academy of Sciences · 76
Immunotherapy based on bispecific T‐cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma
2015 · Jianxuan Zou, Dan Chen, et al. · Cancer Science · 50
PDF
La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease
2018 · Huimin Meng, Xue Sun, et al. · Clinical Immunology · 44
Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
2016 · Dan Chen, Jianxuan Zou, et al. · Immunopharmacology and Immunotoxicology · 29
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance
2020 · Jianxuan Zou, Richard J. Jones, et al. · Journal of Molecular Medicine · 14
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models
2024 · Ram Kumar Singh, Richard J. Jones, et al. · Research Square · 7
PDF
The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma
2020 · Ram Kumar Singh, Richard J. Jones, et al. · Blood · 2
Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma
2017 · Jianxuan Zou, Richard J. Jones, et al. · Blood
Works count: 8
Citation count: 222
H-index: 6
I10-index: 5
Year
Topic
Type